.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,337,324

« Back to Dashboard

Details for Patent: 6,337,324

Title: Pharmaceutical combination
Abstract:The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.
Inventor(s): Harmenberg; Johan Georg (Stockholm, SE), Kristofferson; Ann Harriet Margareta (Sodertalje, SE)
Assignee: Medivir, AB (Huddinge, SE)
Filing Date:Mar 08, 1996
Application Number:08/612,847
Claims:1. A pharmaceutical composition for topical administration comprising a synergistic combination of a topically acceptable antiviral substance which is 1) a herpes-specific nucleoside analogue or an ester, salt or solvate thereof that is preferentially phosphorylated in virus-infected cells or 2) selected from the group consisting of cidofovir, PMEA, PAA and PFA or an ester, salt or solvate thereof, and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier.

2. A pharmaceutical composition for topical administration comprising a synergistic combination of a topically acceptable antiviral substance selected from the group consisting of acyclovir, cidofovir, desciclovir, famciclovir, ganciclovir, lobucavir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and H2G or an ester, salt or solvate thereof and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier.

3. A pharmaceutical composition according to claim 1, wherein the antiinflammatory glucocorticoid is selected from the group consisting of hydrocortisone, alclometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, clobetasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, diflorosane, fluocinolone, fluocortolone, fluticasone, methylprednisolone aceponate, mometasone and rofleponide or an ester, salt or solvate thereof.

4. A pharmaceutical composition according to claim 2, wherein the antiinflammatory glucocorticoid is selected from the group consisting of hydrocortisone, alclometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, clobetasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, diflorosane, fluocinolone, fluocortolone, fluticasone, methylprednisolone aceponate, mometasone and rofleponide or an ester, salt or solvate thereof.

5. A pharmaceutical composition according to claim 1, wherein the antiviral substance is foscarnet and the antiinflammatory glucocorticoid is hydrocortisone, or an ester thereof.

6. A pharmaceutical composition according to claim 1, wherein the antiviral substance is foscarnet and the antiinflammatory glucocorticoid is budesonide, or an ester thereof.

7. A pharmaceutical composition according to claim 1, wherein the antiviral substance is acyclovir, or an ester, salt or solvate thereof, and the antiinflammatory glucocorticoid is hydrocortisone, or an ester thereof.

8. The pharmaceutical composition according to claim 5 comprising 0.1-10% foscarnet and 0.005-3% hydrocortisone.

9. The pharmaceutical composition according to claim 8 comprising 1-5% foscarnet.

10. The pharmaceutical composition according to claim 8 comprising 0.3-3% foscarnet and 0.25-1% hydrocortisone.

11. The pharmaceutical composition according to claim 6 comprising 0.1-10% foscarnet and 0.005-3% budesonide.

12. The pharmaceutical composition according to claim 11 comprising 1-5% foscarnet.

13. The pharmaceutical composition according to claim 7 comprising 0.1-10% acyclovir and 0.005-3% hydrocortisone.

14. The pharmaceutical composition according to claim 13 comprising 1-5% acyclovir.

15. The pharmaceutical composition according to claim 14 comprising 0.25-1% hydrocortisone.

16. A cream, lotion, gel, ointment, plaster, stick or pen containing a pharmaceutical composition according to any one of claims 1-15.

17. A method for the prophylaxis and/or treatment of herpesvirus infections of the skin or mucous membranes in mammals comprising topical administration, in combination or in sequence, of a therapeutically synergistic dose of a topically acceptable antiviral substance which is 1) a herpes-specific nucleoside analogue or an ester, salt or solvate thereof that is preferentially phosphorylated in virus-infected cells or 2) selected from the group consisting of cidofovir, PMEA, PAA and PFA or an ester, salt or solvate thereof and an antiinflammatory glucocorticoid.

18. A method for the prophylaxis and/or treatment of herepesvirus infections of the skin or mucous membranes in mammals comprising topical administration, in combination or in sequence, of a therapeutically synergistic dose of a topically acceptable antiviral substance selected from the group consisting of acyclovir, cidofovir, desciclovir, famciclovir, ganciclovir, lobucavir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and H2G or an ester, salt or solvate thereof and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier.

19. A method according to claim 17, wherein the antiinflammatory glucocorticoid is selected from the group consisting of hydrocortisone, alclometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, clobetasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, diflorosane, fluocinolone, fluocortolone, fluticasone, methylprednisolone aceponate, mometasone and rofleponide or an ester, salt or solvate thereof.

20. A method according to claim 18, wherein the antiinflammatory glucocorticoid is selected from the group consisting of hydrocortisone, alclometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, clobetasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, diflorosane, fluocinolone, fluocortolone, fluticasone, methylprednisolone aceponate, mometasone and rofleponide or an ester, salt or solvate thereof.

21. A method according to claim 17, wherein the antiviral substance is foscarnet and the antiinflammatory glucocorticoid is hydrocortisone, or an ester thereof.

22. A method according to claim 17, wherein the antiviral substance is foscarnet and the antiinflammatory glucocorticoid is budesonide, or an ester thereof.

23. A method according to claim 17, wherein the antiviral substance is acyclovir, or an ester, salt or solvate thereof, and the antiinflammatory glucocorticoid is hydrocortisone, or an ester thereof.

24. A method for the prophylaxis and/or treatment of herpesvirus infections of the skin or mucous membranes in mammals comprising topical administration of a composition according to any one of claims 1-15.

25. A method according to claim 24 wherein the composition is contained in a cream, lotion, gel, ointment, plaster, stick or pen.

26. A method according to any one of claims 17-23, wherein the herpesvirus infection is a recurrent herpesvirus infection.

27. A method according to any one of claims 17-23, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

28. A method according to claim 27, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

29. A method according to claim 26, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

30. A method according to claim 29, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

31. A method according to any one of claims 17-23 wherein the antiviral substance and the glucocorticoid are administered in combination and are contained in a cream, lotion, gel, ointment, plaster, stick or pen.

32. A method according to claim 24, wherein the herpesvirus infection is a recurrent herpesvirus infection.

33. A method according to claim 24, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

34. A method according to claim 33, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

35. A method according to claim 31, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

36. A method according to claim 35, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc